Introduction {#s1}
============

Vasovagal syncope (VVS) is the main form of syncope in children and adolescents and is characterized by syncopal attack and hemodynamic abnormalities during the head-up tilt test (HUTT), including systemic arterial hypotension, bradycardia, or both. It has been reported that VVS accounts for more than 60% of all pediatric syncopal cases ([@B1], [@B2]). Approximately 30% of affected individuals suffer from recurrent syncopal episodes, which significantly impair their quality of life ([@B3], [@B4]). Under such circumstances, efficient interventions are required. However, the exact underlying mechanisms of VVS are not fully understood, which results in an unsatisfactory outcome of treatment to some extent ([@B5], [@B6]). Therefore, elucidation of the complex mechanisms of VVS is particularly important. Fatigue, which is related to energy metabolic dysfunction, is common in patients with VVS ([@B7]). Moreover, it has been established that skeletal muscle extensively accumulates carnitine and acylcarnitines, which are pivotal in cellular energy production because of their role in transporting long-chain fatty acids from the cellular matrix into the matrix of mitochondrion for subsequent beta-oxidation ([@B8], [@B9]). Nevertheless, it is unclear whether a disturbance of carnitine and acylcarnitine profiles is associated with the pathogenesis of VVS. Low sodium intake is one proposed mechanism of VVS and leads to hypovolemia and alterations in biologically active substances which are likely to contribute to syncopal occurrence, including renin, aldosterone, and catecholamine ([@B10]--[@B12]). As a result, supplementation of fluid and sodium is a rationally efficient method to treat VVS ([@B13]). A possible relationship between the metabolism of carnitine and acylcarnitines and the reducing intake of sodium was mentioned among adults with hypertension ([@B14]). However, it is unclear whether low sodium intake in patients with VVS leads to abnormal changes in carnitine and acylcarnitines, which mediates the occurrence of syncope.

Therefore, the present research was undertaken to explore if the low sodium intake is associated with the plasma carnitine and acylcarnitine profile in pediatric VVS patients and discuss the possible underlying mechanisms.

Materials and Methods {#s2}
=====================

Study Subjects
--------------

Twenty-six patients (19 girls and 7 boys, aged 12.5 ± 2.7 years old) with VVS were enrolled in the present research. They visited the Child Syncope Center at Peking University First Hospital from August 2018 to September 2019. All patients underwent an excretion test of 24-h urinary sodium. Based on the excretion levels of 24-h urinary sodium, patients were divided into the group of low urinary sodium excretion (excretion level \<3 g) or the group of normal urinary sodium excretion (excretion level between 3 and 6 g) ([@B2]). No patients were overweight or obese, nor had associated disorders of diabetes mellitus, thyroid dysfunction, renal dysfunction, hepatic dysfunction, or cardiac dysfunction or symptoms and signs of fever, vomiting, diarrhea or dehydration. The criteria for the diagnosis of pediatric VVS were as follows: (1) syncopal events that were often induced by predisposing factors including rapid postural alterations, long-term standing, and emotional stimulation, etc.; (2) a positive response to the HUTT; as well as (3) excluding other syncopal disorders ([@B15], [@B16]). The Ethics Committee of Peking University First Hospital approved this study. We conducted the study in line with the ethical criteria in the Declaration of Helsinki. The legal guardians of each patient signed the informed consent.

Protocol for the HUTT
---------------------

All enrolled patients underwent strict inspections to exclude cardiogenic, neurological, and metabolic disorders. Patients then completed the HUTT. This test was conducted in a dimly lit, warm and quiet room between 8:30 and 12:00 a.m. Patients were required to fast and the medication impacting autonomic nervous function was avoided at least 5 half-life times before the HUTT. They were placed on an autonomic stretcher (HUT-821; Beijing Juchi, Beijing, China) for 10--20 min to maintain a stable hemodynamic condition. Then, they were positioned at 60° passively for as long as 45 min or until a positive response occurred. A positive response to the HUTT was according to the criteria described previously ([@B15], [@B16]).

Protocol for the 24-h Urinary Sodium Excretion Test
---------------------------------------------------

Each patient as well as his/her caretakers were introduced to a standard urine collection process in advance. Girls were required to make a collection of 24-h urine samples during non-menstrual periods. The sodium-selective electrode approach (Cobas 6000, Roche, Basel, Switzerland) was done for measuring the excretion of 24-h urinary sodium. The formula is as follows ([@B17]): excretion of 24-h urinary sodium = concentration of sodium × total 24-h urine volume.

Measurement of Plasma Carnitine and Acylcarnitines
--------------------------------------------------

All VVS patients fasted for at least 4 h before blood sampling at \~8:00 a.m. Two milliliters of blood were drawn by venipuncture and collected in an ethylenediaminetetraacetic acid anticoagulant tube. After being centrifugated at 2,000 g for 20 min, plasma was extracted at 4°C and then preserved at −80°C until tested. The collected plasma was thawed at one time for the measurement of the carnitine and acylcarnitine profile on a tandem mass spectrometer (MS/MS, API3200, Applied Biosystems, California, USA). The concentrations of carnitine and acylcarnitines were calculated automatically using Chemo View software (NeoLynx, Waters, Massachusetts, USA). All the testing work was done by a professionally trained investigator.

Statistical Analysis
--------------------

The data were processed with SPSS software 22.0 (IBM Corp., NY, USA). Continuous variables are stated as the mean ± SD. And between two groups, the differences were measured by Student\'s *t*-test or Mann-Whitney *U*-test according to the Shapiro-Wilk test consequences. Categorical variables are presented as numbers, and Fisher\'s exact test was applied for comparison. A bivariate correlation between data with non-normal distribution was conducted with Spearman\'s correlation coefficients. Significance was considered when *p*-value \<0.05.

Results {#s3}
=======

Basic Information of VVS Patients
---------------------------------

Among the enrolled VVS patients, the group of low urinary sodium excretion included 14 patients with a 24-h urinary sodium excretion of 0.8--2.7 g (mean 2.1 ± 0.6 g), and the group of normal urinary sodium excretion included 12 children with a 24-h urinary sodium excretion of 3.1--5.9 g (mean 3.8 ± 0.8 g). No differences existed in the demographics, and clinical and hemodynamic characteristics between the two groups (*p* \> 0.05, [Table 1](#T1){ref-type="table"}). However, more children in the group of low urinary sodium excretion reported fatigue than in the group of normal urinary sodium excretion (*p* = 0.009, [Table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics and hemodynamics in the head-up tilt test in vasovagal syncope patients.

  **Items**                                 **Low urinary sodium excretion group (*n* = 14)**   **Normal urinary sodium excretion group (*n* = 12)**   ***t/Z/χ*^**2**^ value**              ***p*-value**
  ----------------------------------------- --------------------------------------------------- ------------------------------------------------------ ------------------------------------- ---------------
  Gender (*n*, M/F)                         3/11                                                4/8                                                    ---[^†^](#TN2){ref-type="table-fn"}   0.665
  Age (years)                               12.1 ± 3.0                                          13.0 ± 2.4                                             −0.788                                0.439
  Body mass index (kg/m^2^)                 17.6 ± 2.3                                          20.0 ± 3.9                                             −1.916                                0.067
  Symptom duration (months)                 29.6 ± 37.1[^\*^](#TN1){ref-type="table-fn"}        17.1 ± 19.5[^\*^](#TN1){ref-type="table-fn"}           −0.646                                0.518
  Numbers of syncope (times)                4 ± 3[^\*^](#TN1){ref-type="table-fn"}              4 ± 2[^\*^](#TN1){ref-type="table-fn"}                 −1.157                                0.247
  Duration of unconsciousness (min)         5.2 ± 8.3[^\*^](#TN1){ref-type="table-fn"}          1.5 ± 1.7[^\*^](#TN1){ref-type="table-fn"}             −1.066                                0.286
  Fatigue (*n*, yes/no)                     13/1                                                5/7                                                    ---[^†^](#TN2){ref-type="table-fn"}   0.009
  Supine HR (beats/min)                     77 ± 14[^\*^](#TN1){ref-type="table-fn"}            77 ± 14                                                −0.180                                0.857
  Supine SBP (mmHg)                         106 ± 9                                             110 ± 11[^\*^](#TN1){ref-type="table-fn"}              −1.185                                0.236
  Supine DBP (mmHg)                         62 ± 6                                              66 ± 9                                                 −1.070                                0.295
  Time to positive response in HUTT (min)   31 ± 11[^\*^](#TN1){ref-type="table-fn"}            26 ± 13                                                −1.159                                0.246
  Positive HR in HUTT (beats/min)           116 ± 32                                            114 ± 16                                               0.270                                 0.789
  Positive SBP in HUTT (mmHg)               72 ± 5                                              71 ± 5                                                 0.567                                 0.576
  Positive DBP in HUTT (mmHg)               48 ± 7[^\*^](#TN1){ref-type="table-fn"}             48 ± 4                                                 −0.438                                0.661

*HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; HUTT, head-up tilt test; Data are mean ± SD or numbers*.

*Non-normality*.

*Fisher\'s exact test*.

Plasma Carnitine and Acylcarnitine Profile in VVS Patients
----------------------------------------------------------

Levels of several acylcarnitines, namely tiglylcarnitine (C5:1) (*p* = 0.048), hydroxyhexadecanoylcarnitine (C16OH) (*p* = 0.048), hydroxyoctadecanoylcarnitine (C18OH) (*p* = 0.048), and carnitine C22 (*p* = 0.048), were higher in the group of low urinary sodium excretion than in the group of normal urinary sodium excretion ([Table 2](#T2){ref-type="table"}). No statistically significant differences were showed between the two groups in other acylcarnitines or free carnitine (C2, *p* = 0.504; C3, *p* = 0.777; C3DC, *p* = 0.803; C4, *p* = 0.620; C5, *p* = 1.000; C5DC, *p* = 0.912; C5OH, *p* = 0.654; C6, *p* = 0.312; C6DC, *p* = 0.354; C8, *p* = 0.288; C8:1, *p* = 0.313; C10, *p* = 0.359; C10:1, *p* = 0.086; C10:2, *p* = 0.192; C12, *p* = 0.720; C12:1, *p* = 0.083; C14, *p* = 0.845; C14:1, *p* = 0.565; C14:2, *p* = 0.146; C14DC, *p* = 0.181; C14OH, *p* = 0.234; C16, *p* = 0.897; C16:1, *p* = 0.863; C16:1OH, *p* = 0.725; C18, *p* = 0.958; C18:1, *p* = 0.813; C18:1OH, *p* = 0.481; C18:2, *p* = 0.813; C20, *p* = 0.105; C24, *p* = 0.457; C26, *p* = 0.355; C5/C2, *p* = 0.297; C2/C0, *p* = 0.366; C3/C2, *p* = 0.602; C3/C0, *p* = 1.000; C8/C2, *p* = 0.867; C14:1/C16, *p* = 0.909; free carnitine, *p* = 0.897, [Table 2](#T2){ref-type="table"}).

###### 

Plasma carnitine and acylcarnitines in vasovagal syncope patients.

  **Items**        **Low urinary sodium excretion group (*n* = 14)**   **Normal urinary sodium excretion group (*n* = 12)**   ***t/Z* value**   ***p-*value**
  ---------------- --------------------------------------------------- ------------------------------------------------------ ----------------- ---------------
  Free carnitine   23.657 ± 5.937                                      23.388 ± 4.33                                          0.130             0.897
  C2               3.110 ± 1.237                                       2.885 ± 1.005[^\*^](#TN3){ref-type="table-fn"}         −0.669            0.504
  C3               0.204 ± 0.066                                       0.206 ± 0.071[^\*^](#TN3){ref-type="table-fn"}         −0.284            0.777
  C3DC             0.019 ± 0.010[^\*^](#TN3){ref-type="table-fn"}      0.018 ± 0.006[^\*^](#TN3){ref-type="table-fn"}         −0.249            0.803
  C4               0.101 ± 0.039                                       0.108 ± 0.038                                          −0.502            0.620
  C5               0.045 ± 0.015                                       0.045 ± 0.016                                          0.000             1.000
  C5:1             0.013 ± 0.005[^\*^](#TN3){ref-type="table-fn"}      0.010 ± 0.000                                          −1.974            0.048
  C5DC             0.054 ± 0.023[^\*^](#TN3){ref-type="table-fn"}      0.047 ± 0.010[^\*^](#TN3){ref-type="table-fn"}         −0.110            0.912
  C5OH             0.029 ± 0.010[^\*^](#TN3){ref-type="table-fn"}      0.027 ± 0.005[^\*^](#TN3){ref-type="table-fn"}         −0.448            0.654
  C6               0.032 ± 0.012                                       0.029 ± 0.012[^\*^](#TN3){ref-type="table-fn"}         −1.012            0.312
  C6DC             0.052 ± 0.022[^\*^](#TN3){ref-type="table-fn"}      0.041 ± 0.007[^\*^](#TN3){ref-type="table-fn"}         −0.926            0.354
  C8               0.068 ± 0.026                                       0.061 ± 0.032[^\*^](#TN3){ref-type="table-fn"}         −1.063            0.288
  C8:1             0.125 ± 0.035                                       0.122 ± 0.064[^\*^](#TN3){ref-type="table-fn"}         −1.009            0.313
  C10              0.086 ± 0.033                                       0.073 ± 0.035                                          0.935             0.359
  C10:1            0.102 ± 0.023                                       0.092 ± 0.034[^\*^](#TN3){ref-type="table-fn"}         −1.715            0.086
  C10:2            0.021 ± 0.006[^\*^](#TN3){ref-type="table-fn"}      0.018 ± 0.006[^\*^](#TN3){ref-type="table-fn"}         −1.305            0.192
  C12              0.029 ± 0.012                                       0.028 ± 0.015[^\*^](#TN3){ref-type="table-fn"}         −0.359            0.720
  C12:1            0.052 ± 0.015[^\*^](#TN3){ref-type="table-fn"}      0.043 ± 0.014[^\*^](#TN3){ref-type="table-fn"}         −1.732            0.083
  C14              0.019 ± 0.010[^\*^](#TN3){ref-type="table-fn"}      0.018 ± 0.012[^\*^](#TN3){ref-type="table-fn"}         −0.195            0.845
  C14:1            0.047 ± 0.013                                       0.045 ± 0.012[^\*^](#TN3){ref-type="table-fn"}         −0.575            0.565
  C14:2            0.019 ± 0.007[^\*^](#TN3){ref-type="table-fn"}      0.016 ± 0.009[^\*^](#TN3){ref-type="table-fn"}         −1.452            0.146
  C14DC            0.011 ± 0.004[^\*^](#TN3){ref-type="table-fn"}      0.010 ± 0.000                                          −1.336            0.181
  C14OH            0.006 ± 0.005[^\*^](#TN3){ref-type="table-fn"}      0.003 ± 0.005[^\*^](#TN3){ref-type="table-fn"}         −1.190            0.234
  C16              0.114 ± 0.118[^\*^](#TN3){ref-type="table-fn"}      0.110 ± 0.095[^\*^](#TN3){ref-type="table-fn"}         −0.130            0.897
  C16:1            0.016 ± 0.012[^\*^](#TN3){ref-type="table-fn"}      0.015 ± 0.008[^\*^](#TN3){ref-type="table-fn"}         −0.173            0.863
  C16:1OH          0.006 ± 0.008[^\*^](#TN3){ref-type="table-fn"}      0.004 ± 0.005[^\*^](#TN3){ref-type="table-fn"}         −0.352            0.725
  C16OH            0.003 ± 0.005[^\*^](#TN3){ref-type="table-fn"}      0.000 ± 0.000                                          −1.974            0.048
  C18              0.036 ± 0.032[^\*^](#TN3){ref-type="table-fn"}      0.038 ± 0.037[^\*^](#TN3){ref-type="table-fn"}         −0.053            0.958
  C18:1            0.118 ± 0.125[^\*^](#TN3){ref-type="table-fn"}      0.101 ± 0.100[^\*^](#TN3){ref-type="table-fn"}         −0.237            0.813
  C18:1OH          0.003 ± 0.005[^\*^](#TN3){ref-type="table-fn"}      0.002 ± 0.004[^\*^](#TN3){ref-type="table-fn"}         −0.704            0.481
  C18:2            0.076 ± 0.073[^\*^](#TN3){ref-type="table-fn"}      0.063 ± 0.056[^\*^](#TN3){ref-type="table-fn"}         −0.236            0.813
  C18OH            0.003 ± 0.005[^\*^](#TN3){ref-type="table-fn"}      0.000 ± 0.000                                          −1.974            0.048
  C20              0.004 ± 0.005[^\*^](#TN3){ref-type="table-fn"}      0.001 ± 0.003[^\*^](#TN3){ref-type="table-fn"}         −1.620            0.105
  C22              0.003 ± 0.005[^\*^](#TN3){ref-type="table-fn"}      0.000 ± 0.000                                          −1.974            0.048
  C24              0.009 ± 0.003[^\*^](#TN3){ref-type="table-fn"}      0.008 ± 0.004[^\*^](#TN3){ref-type="table-fn"}         −0.743            0.457
  C26              0.009 ± 0.003[^\*^](#TN3){ref-type="table-fn"}      0.010 ± 0.000                                          −0.926            0.355
  C5/C2            0.014 ± 0.006[^\*^](#TN3){ref-type="table-fn"}      0.017 ± 0.007[^\*^](#TN3){ref-type="table-fn"}         −1.043            0.297
  C2/C0            0.121 ± 0.043[^\*^](#TN3){ref-type="table-fn"}      0.108 ± 0.029[^\*^](#TN3){ref-type="table-fn"}         −0.905            0.366
  C3/C2            0.069 ± 0.027[^\*^](#TN3){ref-type="table-fn"}      0.075 ± 0.028                                          −0.522            0.602
  C3/C0            0.010 ± 0.000                                       0.010 ± 0.000                                          0.000             1.000
  C8/C2            0.021 ± 0.009                                       0.022 ± 0.006[^\*^](#TN3){ref-type="table-fn"}         −0.167            0.867
  C14:1/C16        0.736 ± 0.373                                       0.717 ± 0.465                                          0.116             0.909

*Data are mean ± SD*.

*Non-normality*.

Correlations Between the Excretion of 24-h Urinary Sodium and Plasma Acylcarnitines
-----------------------------------------------------------------------------------

Further examining the association between the excretion levels of 24-h urinary sodium and the abovementioned plasma acylcarnitines with significant difference, negative Spearman\'s correlation coefficients were found (C5:1, *r* = −0.469, *p* = 0.016; C16OH, *r* = −0.469, *p* = 0.016; C18OH, *r* = −0.469, *p* = 0.016; and C22, *r* = −0.469, *p* = 0.016) in all study patients.

Discussion {#s4}
==========

In mitochondria, carnitine and acylcarnitines are a series of essential molecules that play an obligatory part in the long-chain fatty acid beta-oxidation. Analyzing carnitine and acylcarnitine profile may help in the investigation and elucidation of metabolic derangements. The acylcarnitine profile displays a characteristic alteration in inherited metabolic diseases, such as short chain and medium chain acyl coenzyme A dehydrogenase deficiency, and carnitine acylcarnitine translocase deficiency ([@B18]). Moreover, it was reported that changes in the acylcarnitine profile were related to the development of IgA nephropathy and diabetes mellitus ([@B19], [@B20]). In the study, we observed that in VVS patients, some plasma acylcarnitines (C5:1, C16OH, C18OH, C22) were higher in the group of low urinary sodium excretion than in the group of normal urinary sodium excretion. Moreover, the excretion of 24-h urinary sodium was negatively correlated with these plasma acylcarnitines. Patients suffering from VVS with low urinary sodium excretion were more susceptible to experiencing symptoms of fatigue than those in the group of normal urinary sodium excretion.

The mechanisms by which low sodium loading results in a disturbed acylcarnitine profile have not been explored. Derkach et al. also found a phenomenon in a DASH-sodium trial among participants with high blood pressure, that plasma metabolites of acylcarnitines (butyrylcarnitine and valerylcarnitine) were increased with sodium reduction ([@B14]). On the other hand, some studies showed a significant increase in renin-angiotensin-aldosterone system activity with low sodium intake ([@B12]). The activated renin-angiotensin-aldosterone system is capable of inducing oxidative stress ([@B21], [@B22]), which could diminish the activity of enzymes in metabolic processes. Therefore, we inferred that low sodium loading might impair the activity of enzymes involved in the long-chain fatty acid beta-oxidation. The inefficient long-chain fatty acid beta-oxidation could promote the accumulation of acylcarnitine byproducts from substrate catabolism, which are capable of passing across the mitochondrial membrane and the cell membrane ([@B19], [@B23], [@B24]). More convincingly, 24-h urinary sodium excretion was found to be negatively correlated with the concentration of several acylcarnitines in our study, which suggested that reduced dietary sodium intake might be associated with abnormal fatty acid metabolism.

As a high-energy-consuming organ, skeletal muscle needs fatty acids to supplement essential energy during exercise or stress ([@B25]). Insufficient energy leads to fatigue. Large numbers of VVS patients complain of fatigue before or after syncope occurrence ([@B7]). In our Syncope Unit, we also observed several patients experiencing fatigue for long durations of time. In the present study, patients with low urinary sodium excretion were more prone to experience fatigue than those with normal urinary sodium excretion. This highlights that some VVS patients are disturbed by energy metabolism dysfunction, which is likely induced, at least in part, by low sodium intake.

The excretion of 24-h urinary sodium, a standard criterion for the measurement of sodium intake ([@B26]), is applied in many investigations to explore the relationship between sodium intake and development of diverse disorders. Kieneker et al. conducted a study in 7,330 individuals and found a strong relationship between low urinary sodium level and an increased stroke risk ([@B27]). Moreover, many investigations have showed that abnormal sodium intake is related to increased mortality and cardiovascular events ([@B28], [@B29]). The relationship between sodium intake and outcomes of health should be a U-shape, where high and low sodium intake indicated a risk factor for negative outcomes. We suggested that low sodium intake might decrease the long-chain fatty acid beta-oxidation rate and increase the plasma concentration of acylcarnitines in VVS patients. Additional and longer investigations should be performed to determine whether low sodium intake can predict the outcomes of affected individuals.

In summary, increased plasma concentration of acylcarnitines in VVS patients with low urinary sodium excretion was reported for the first time. In addition to VVS, postural tachycardia syndrome is another subtype of orthostatic intolerance with fatigue, palpitation and dizziness as well as syncope in the childhood ([@B30], [@B31]). Furthermore, some postural tachycardia syndrome patients are also characterized with low sodium intake ([@B32], [@B33]). As such, we speculate that the restricted sodium intake- induced disturbance of plasma acylcarnitines and cellular energy metabolism might be associated with the pathogenesis of not only VVS, but also other subtypes of orthostatic intolerance in children, which merits further investigations. Also, there were some limitations, such as a small sample size, the single-center observational study design and the lack of healthy control participants. Future multicenter-based, larger sample-sized and mechanistic studies should be performed to explore the significance of low-sodium-intake-associated energy metabolism in pathogenesis of VVS.
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VVS

:   vasovagal syncope

HUTT

:   head-up tilt test.
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